Tim Reiner has been appointed as Mundipharmaâ€™s Head of Business Development for Asia, Latin America and the Middle East/North Africa with effect from 1 June, 2013, to further strengthen the companyâ€™s presence in key growth regions.
Tim joins Mundipharma Pte. Ltd. from McKinsey where he spent the last 7 years on the McKinsey Global Rotation Program, leading more than 55 consulting projects across pharmaceutical, consumer, and other healthcare and industrial clients. Since 2010, he was one of the leaders in McKinseyâ€™s EMEA Pharmaceutical and Medical Products Practice, and co-founded the Healthcare/Private Equity practice joint-venture.
During his tenure, in addition to his client service, he led the development of McKinseyâ€™s standard approach for pharmaceutical and medical product diligences, and served as faculty at McKinseyâ€™s internal private equity and due diligence trainings. Prior to McKinsey, Tim worked with a mid-market private equity fund and the University of Minnesotaâ€™s Ventures Enterprise to identify investment opportunities in biopharmaceuticals and other industries.
Raman Singh, Regional Director, Asia Pacific, Latin America, Middle East and Africa, said, â€śWe are delighted to have Tim on board with Mundipharma in Singapore, bringing his rich experience and proven leadership abilities in pharmaceutical and medical products practices across multiple important markets globally. Having him head our business development in Asia, Latin American, and the Middle East/North Africa will bring positive growth and help Mundipharma further strengthen our operations throughout these developing regions.â€ť
Tim Reiner, who relocated to Singapore in June, said, â€śIâ€™m excited to be joining Mundipharma, a company with such wide reach globally, and that has been delivering consistently high quality products in the field of pain management. Itâ€™s great to be part of a company still very open to exploring new fields and dedicated to expanding its business for patients worldwide.â€ť
Click here for the complete issue.